should take the main responsibility (1), and I still think that this is necessary.

The warning against initiatives by regional or specialized groups may seem justified, and I certainly agree that standardization is an international issue (1, 2). I have been involved in projects organized by the International Society for Onco developmental Biology and Medicine, which apparently is what Lequin considers a “specialized group”, aimed at mapping the epitopes of PSA and hCG. Well-characterized antibodies and standards are necessary for establishment of reference methods, but much work remains for the international organizations mentioned by Lequin before such methods can be established. I think that we need more projects of this kind rather than more restrictions.

References

Marco Di Tola
Luigi Sabbatella
Antonio Picarelli*

Department of Clinical Sciences
University of Rome “La Sapienza”
155-00161 Rome, Italy

*Address correspondence to this author at: Department of Clinical Sciences, Policlinico “Umberto I”, University of Rome “La Sapienza”, Viale del Policlinico, 155-00161 Rome, Italy. Fax 39-06-49970524; e-mail a.picarelli@flashnet.it.

The authors of the article cited above respond:

To the Editor:

In the report cited above, we examined the diagnosis of celiac disease in our patients (none of whom had an IgA deficiency) by determination of IgA anti-gliadin and IgA anti-tissue transglutaminase (tTG). Drs. Di Tola et al. indicate that IgG1 anti-endomysial antibody determinations can also be useful for this purpose, which would support their theory that transglutaminase is not the only an-

References